Նովո Նորդիսկ (N1VO34) Stock Price & News

Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia

About Նովո Նորդիսկ

CEOMike Doustdar

Employees66,7 հզր

Founded1923

HeadquartersBagsværd, Մայրաքաղաքային տարածաշրջան, Դանիա

Sector-

Websitenovonordisk.com

All values in DKK	2025 թ. սեպ	2025 թ. դեկ	2026 թ. մրտ	2026 թ. հնս
Revenue	74,98 մլրդ	79,14 մլրդ	96,82 մլրդ	78,49 մլրդ
Cost of goods sold	14,47 մլրդ	14,17 մլրդ	13,60 մլրդ	17,10 մլրդ
Cost of revenue	14,47 մլրդ	14,17 մլրդ	13,60 մլրդ	17,10 մլրդ
Research and development expenses	11,49 մլրդ	12,67 մլրդ	10,28 մլրդ	11,46 մլրդ
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	15,76 մլրդ	17,14 մլրդ	13,22 մլրդ	16,31 մլրդ
Operating expense	27,25 մլրդ	29,73 մլրդ	23,61 մլրդ	28,00 մլրդ
Total operating expenses	41,72 մլրդ	43,90 մլրդ	37,20 մլրդ	45,10 մլրդ
Operating income	33,25 մլրդ	35,24 մլրդ	59,62 մլրդ	33,39 մլրդ
Other non operating income	1,53 մլրդ	-241,00 մլն	-	-
EBT including unusual items	25,52 մլրդ	34,18 մլրդ	62,17 մլրդ	26,88 մլրդ
EBT excluding unusual items	35,09 մլրդ	37,62 մլրդ	62,17 մլրդ	33,20 մլրդ
Income tax expense	5,51 մլրդ	7,29 մլրդ	13,62 մլրդ	5,89 մլրդ
Effective tax rate	21,60%	21,34%	21,90%	21,90%
Other operating expenses	-	-81,00 մլն	106,00 մլն	234,00 մլն
Net income	20,01 մլրդ	26,89 մլրդ	48,56 մլրդ	20,99 մլրդ
Net profit margin	26,68%	33,98%	50,15%	26,74%
Earnings per share	4,50	6,04	6,63	6,18
Interest and investment income	307,00 մլն	4,41 մլրդ	-	1,31 մլրդ
Interest expense	-	-4,97 մլրդ	-	-1,50 մլրդ
Net interest expenses	307,00 մլն	-560,00 մլն	-	-186,00 մլն
Depreciation and amortization charges	-	-	-	-
EBITDA	36,49 մլրդ	36,66 մլրդ	63,13 մլրդ	36,99 մլրդ
Gain or loss from assets sale	-	-	-	-

Ask anything